000157056 001__ 157056
000157056 005__ 20240229123127.0
000157056 0247_ $$2doi$$a10.1186/s13014-020-01613-4
000157056 0247_ $$2pmid$$apmid:32653003
000157056 037__ $$aDKFZ-2020-01347
000157056 041__ $$aeng
000157056 082__ $$a610
000157056 1001_ $$0P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aBostel, Tilmann$$b0$$eFirst author$$udkfz
000157056 245__ $$aExploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI.
000157056 260__ $$aLondon$$bBioMed Central$$c2020
000157056 3367_ $$2DRIVER$$aarticle
000157056 3367_ $$2DataCite$$aOutput Types/Journal article
000157056 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1612509211_8338
000157056 3367_ $$2BibTeX$$aARTICLE
000157056 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157056 3367_ $$00$$2EndNote$$aJournal Article
000157056 500__ $$a#EA:E050#LA:E050#
000157056 520__ $$aTo date, only limited magnetic resonance imaging (MRI) data are available concerning tumor regression during neoadjuvant radiochemotherapy (RCT) of rectal cancer patients, which is a prerequisite for adaptive radiotherapy (RT) concepts. This exploratory study prospectively evaluated daily fractional MRI during neoadjuvant treatment to analyze the predictive value of MR biomarkers for treatment response.Locally advanced rectal cancer patients were examined with daily MRI during neoadjuvant RCT. Contouring of the tumor volume was performed for each MRI scan by using T2- and diffusion-weighted-imaging (DWI)-sequences. The daily apparent-diffusion coefficient (ADC) was calculated. Volumetric and functional tumor changes during RCT were analyzed and correlated with the pathological response after surgical resection.In total, 171 MRI scans of eight patients were analyzed regarding anatomical and functional dynamics during RCT. Pathological complete response (pCR) could be achieved in four patients, and four patients had a pathological partial response (pPR) following neoadjuvant treatment. T2- and DWI-based volumetry proved to be statistically significant in terms of therapeutic response, and volumetric thresholds at week two and week four during RCT were defined for the prediction of pCR. In contrast, the average tumor ADC values widely overlapped between both response groups during RCT and appeared inadequate to predict treatment response in our patient cohort.This prospective exploratory study supports the hypothesis that MRI may be able to predict pCR of rectal cancers early during neoadjuvant RCT. Our data therefore provide a useful template to tailor future MR-guided adaptive treatment concepts.
000157056 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000157056 588__ $$aDataset connected to CrossRef, PubMed,
000157056 7001_ $$0P:(DE-He78)b9af25eb669871c3bd619dff8c5c34c0$$aDreher, C.$$b1$$udkfz
000157056 7001_ $$aWollschläger, D.$$b2
000157056 7001_ $$aMayer, A.$$b3
000157056 7001_ $$0P:(DE-He78)b03f7e5246e8a54dc8b9664fa11324e2$$aKönig, F.$$b4$$udkfz
000157056 7001_ $$0P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9$$aBickelhaupt, S.$$b5$$udkfz
000157056 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, H. P.$$b6$$udkfz
000157056 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, P. E.$$b7$$udkfz
000157056 7001_ $$0P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aSterzing, Florian$$b8
000157056 7001_ $$0P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a$$aBäumer, Philipp$$b9
000157056 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, J.$$b10$$udkfz
000157056 7001_ $$0P:(DE-HGF)0$$aNicolay, N. H.$$b11$$eLast author
000157056 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-020-01613-4$$gVol. 15, no. 1, p. 171$$n1$$p171$$tRadiation oncology$$v15$$x1748-717X$$y2020
000157056 909CO $$ooai:inrepo02.dkfz.de:157056$$pVDB
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b9af25eb669871c3bd619dff8c5c34c0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b03f7e5246e8a54dc8b9664fa11324e2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000157056 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000157056 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000157056 9141_ $$y2020
000157056 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-12
000157056 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-12
000157056 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-12
000157056 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000157056 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000157056 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000157056 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x1
000157056 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x2
000157056 9201_ $$0I:(DE-He78)E250-20160331$$kE250$$lMuliparametrische Methoden zur Früherkennung des Prostatakarzinoms$$x3
000157056 980__ $$ajournal
000157056 980__ $$aVDB
000157056 980__ $$aI:(DE-He78)E050-20160331
000157056 980__ $$aI:(DE-He78)E055-20160331
000157056 980__ $$aI:(DE-He78)E010-20160331
000157056 980__ $$aI:(DE-He78)E250-20160331
000157056 980__ $$aUNRESTRICTED